Minato, A.; Furubayashi, N.; Nagata, Y.; Tomoda, T.; Masaoka, H.; Song, Y.; Hori, Y.; Kiyoshima, K.; Negishi, T.; Kuroiwa, K.;
et al. Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study. Curr. Oncol. 2024, 31, 862-871.
https://doi.org/10.3390/curroncol31020064
AMA Style
Minato A, Furubayashi N, Nagata Y, Tomoda T, Masaoka H, Song Y, Hori Y, Kiyoshima K, Negishi T, Kuroiwa K,
et al. Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study. Current Oncology. 2024; 31(2):862-871.
https://doi.org/10.3390/curroncol31020064
Chicago/Turabian Style
Minato, Akinori, Nobuki Furubayashi, Yujiro Nagata, Toshihisa Tomoda, Hiroyuki Masaoka, Yoohyun Song, Yoshifumi Hori, Keijiro Kiyoshima, Takahito Negishi, Kentaro Kuroiwa,
and et al. 2024. "Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study" Current Oncology 31, no. 2: 862-871.
https://doi.org/10.3390/curroncol31020064
APA Style
Minato, A., Furubayashi, N., Nagata, Y., Tomoda, T., Masaoka, H., Song, Y., Hori, Y., Kiyoshima, K., Negishi, T., Kuroiwa, K., Seki, N., Tomisaki, I., Harada, K., Nakamura, M., & Fujimoto, N.
(2024). Prognostic Impact of Histologic Subtype and Divergent Differentiation in Patients with Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multicenter Retrospective Study. Current Oncology, 31(2), 862-871.
https://doi.org/10.3390/curroncol31020064
